Results 311 to 320 of about 479,990 (331)
Some of the next articles are maybe not open access.
Acute Treatment of Ischemic Stroke
Neurologic Clinics, 2022Ischemic stroke affects 2.5% of the population of the United States and is the leading cause of disability. This article outlines the evidence to support intravenous thrombolysis with alteplase and tenecteplase, thrombolysis in the setting of DWI/flair mismatch, endovascular treatment in the 6-hour and 6- to 24-hour window, and the use of telemedicine ...
Jana J Wold, Stephanie Lyden
openaire +2 more sources
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2010
Stroke is the third most common cause of death in the United States and is the number one cause of long‐term disability. Legislative mandates, largely the result of the American Heart Association, American Stroke Association, and Brain Attack Coalition working cooperatively, have resulted in nationwide standardization of care for patients who ...
Carolyn Piazza +5 more
openaire +2 more sources
Stroke is the third most common cause of death in the United States and is the number one cause of long‐term disability. Legislative mandates, largely the result of the American Heart Association, American Stroke Association, and Brain Attack Coalition working cooperatively, have resulted in nationwide standardization of care for patients who ...
Carolyn Piazza +5 more
openaire +2 more sources
Role of imaging in current acute ischemic stroke workflow for endovascular therapy.
Stroke, 2015Ischemic stroke is caused by a thrombus that blocks an intracranial artery. Brain tissue beyond the blocked artery survives for a variable period of time because of blood and nutrients received through tiny vessels called collaterals.
B. Menon, B. Campbell, C. Levi, M. Goyal
semanticscholar +1 more source
2017
The primary focus for the initial treatment of acute ischemic stroke is determining whether a patient who presents with acute neurological deficits is a candidate for intravenous (IV) thrombolytic therapy. Within the last two decades, the use of IV alteplase (tPA) for acute ischemic stroke together with the establishment of stroke systems of care has ...
Karin Nystrom, Joseph Schindler
openaire +4 more sources
The primary focus for the initial treatment of acute ischemic stroke is determining whether a patient who presents with acute neurological deficits is a candidate for intravenous (IV) thrombolytic therapy. Within the last two decades, the use of IV alteplase (tPA) for acute ischemic stroke together with the establishment of stroke systems of care has ...
Karin Nystrom, Joseph Schindler
openaire +4 more sources
Journal of Neuroscience Nursing, 2007
More than 700,000 people have a stroke each year in the United States. A diagnosis of stroke formerly elicited a nihilistic approach, but this has substantially changed in the last decade. Currently, time is brain, and it is important for all disciplines to work together to initiate acute stroke protocols in the emergency department and identify ...
Janice L. Hinkle, Mary Guanci
openaire +3 more sources
More than 700,000 people have a stroke each year in the United States. A diagnosis of stroke formerly elicited a nihilistic approach, but this has substantially changed in the last decade. Currently, time is brain, and it is important for all disciplines to work together to initiate acute stroke protocols in the emergency department and identify ...
Janice L. Hinkle, Mary Guanci
openaire +3 more sources
Acute Ischemic Stroke and Hyperglycemia
Critical Care Nursing Quarterly, 2014To increase the comprehension about the profound effects of hyperglycemia within the first 48 hours poststroke on the outcomes of acute ischemic stroke, the authors reviewed multiple studies and literature reviews. Research supports the detrimental effects of hyperglycemia on the morbidity and mortality of patients diagnosed with acute ischemic stroke.
Laura Pittiglio +2 more
openaire +3 more sources
Treatment of Acute Ischemic Stroke
New England Journal of Medicine, 2000Ischemic stroke exacts a heavy toll in death and disability worldwide. In the United States, where it is the third leading cause of death and the leading cause of serious long-term disability, approximately 750,000 strokes occur annually, with an annual mortality rate exceeding 150,000.1–4 In June 1996, the Food and Drug Administration (FDA) approved ...
Thomas Brott, Julien Bogousslavsky
openaire +3 more sources
Acute Ischemic Stroke and Infections
Journal of Stroke and Cerebrovascular Diseases, 2011We present an overview of multiple infections in relation to acute ischemic stroke and the therapeutic options available. Conditions that are a direct cause of stroke (infectious endocarditis, meningoencephalitides, and human immunodeficiency virus infection), the pathophysiologic mechanism responsible for stroke, and treatment dilemmas are presented ...
Kevin J. Gibbons +11 more
openaire +3 more sources
Acute Ischemic Stroke Management
Thrombosis Research, 2000The use of thrombolytic therapy represents one of many recent developments in the management of acute ischemic stroke. The development of stroke teams and protocols has been driven by these new demands for an urgent response to ischemic stroke. The short time window of 3 hours for therapy with intravenous recombinant tissue plasminogen activator ...
Richard P. Atkinson +1 more
openaire +3 more sources
Alteplase for acute ischemic stroke
Expert Review of Cardiovascular Therapy, 2006Alteplase, an intravenously administered form of recombinant tissue plasminogen activator (rt-PA), remains the only US FDA-approved thrombolytic treatment for acute ischemic stroke within 3 h of symptom onset. Patients treated with intravenous rt-PA are at least 30% more likely to have minimal or no disability at 3 months compared with placebo. Despite
Nicole R. Gonzales, James C. Grotta
openaire +2 more sources